Alpha-thalassemia is an inherited blood disorder where your body doesn’t produce enough of one key protein needed to build hemoglobin, the molecule in red blood cells that carries oxygen. The condition ranges from completely silent (no symptoms at all) to fatal before birth, depending on how many of the four genes responsible are affected. It’s most common in people with ancestry from Southeast Asia, the Mediterranean, and sub-Saharan Africa.
How Four Genes Control the Condition
Normal hemoglobin is built from two types of protein chains: alpha and beta. You inherit four genes that produce the alpha chain, two from each parent. Alpha-thalassemia occurs when one or more of these four genes is deleted or damaged, reducing the amount of alpha chains your body can make. The fewer working genes you have, the more severe the condition.
This creates a spectrum of four distinct forms:
- Silent carrier (1 gene affected): No symptoms, normal blood tests. Most people never know they carry it unless genetic testing reveals it.
- Alpha-thalassemia trait (2 genes affected): Mild anemia. Red blood cells are smaller than normal but most people feel fine.
- Hemoglobin H disease (3 genes affected): Moderate to severe anemia that often requires medical management.
- Alpha-thalassemia major, or Hb Bart syndrome (all 4 genes affected): The most severe form. Without intervention, it is fatal before or shortly after birth.
What Happens Inside Your Blood
When you don’t make enough alpha chains, the beta chains that would normally pair with them are left unmatched. These excess beta chains are unstable on their own. They clump together into insoluble deposits inside developing red blood cells, damaging cell membranes and triggering the cells to self-destruct prematurely. In severe cases, this process destroys 60 to 80 percent of red blood cell precursors in the bone marrow before they ever reach the bloodstream.
The unmatched chains also generate harmful oxygen radicals that further damage the cell’s structural proteins. This combination of premature cell death in the bone marrow and destruction of circulating red blood cells is what drives the anemia. In milder forms (one or two genes affected), the imbalance is small enough that your body compensates without trouble.
Symptoms by Severity
Silent carriers have no symptoms at all. Their red blood cells may be slightly smaller than average, but this rarely shows up on routine bloodwork and has no effect on daily life. The only practical significance is the possibility of passing the affected gene to children.
People with alpha-thalassemia trait sometimes have mild anemia that can be mistaken for iron deficiency. The key difference is that iron supplements won’t fix it. You might feel slightly more tired than usual, but many people with the trait live their entire lives without realizing they have it.
Hemoglobin H disease is where the condition starts to have a real daily impact. Hemoglobin levels typically run between 7 and 10 g/dL (normal is roughly 12 to 16). Symptoms include fatigue, pale skin, an enlarged spleen, and jaundice. Fevers, infections, and exposure to certain medications can trigger episodes where red blood cells break down more rapidly, sometimes dropping hemoglobin low enough to require a blood transfusion.
Alpha-thalassemia major causes severe anemia and massive fluid buildup in the fetus, a condition called hydrops fetalis. It also carries serious risks for the mother during pregnancy, including dangerously high blood pressure and other complications.
How It’s Diagnosed
A standard complete blood count (CBC) is usually the first clue. People with alpha-thalassemia trait tend to have notably small red blood cells, with average cell volume in the 65 to 75 femtoliter range (normal is about 80 to 100). Silent carriers may have cells only slightly below normal, around 75 to 85 fL, which is easy to overlook.
Newborn screening can detect moderate and severe forms by measuring an abnormal hemoglobin called Hb Bart. In alpha-thalassemia trait, Hb Bart makes up about 5 to 6 percent of total hemoglobin at birth. In Hemoglobin H disease, it accounts for 15 to 30 percent. Silent carriers show only 1 to 2 percent, which can slip below detection thresholds.
Genetic (DNA) testing is the definitive way to confirm alpha-thalassemia and determine exactly how many genes are affected. This matters most for family planning, because two carriers can potentially have a child with a severe form.
Who Is Most at Risk
Alpha-thalassemia is one of the most common genetic conditions in the world, concentrated in tropical and subtropical regions where malaria has historically been prevalent. Carrying one or two affected genes appears to offer some protection against malaria, which is why the trait became so widespread in those populations over thousands of years.
The intermediate and severe forms (Hemoglobin H disease and alpha-thalassemia major) are most frequently seen in families from Southeast Asia, southern China, and Mediterranean countries. In North America and Northern Europe, these severe forms are rare in the general population and occur predominantly in immigrant communities from those regions.
Living With Hemoglobin H Disease
Most people with Hemoglobin H disease manage the condition without regular transfusions. Daily folic acid supplementation helps support red blood cell production. The main precaution is avoiding medications and chemicals known to cause red blood cell breakdown, particularly those that are also dangerous for people with G6PD deficiency (a related enzyme condition). Your doctor can provide a specific list, but common examples include certain antibiotics and anti-malarial drugs.
Blood transfusions become necessary when hemoglobin drops below about 6 g/dL, which can happen during acute illness or hemolytic episodes. Some subtypes of Hemoglobin H disease, particularly one called Hemoglobin H-Constant Spring, tend to be more severe and can lead to iron overload even without frequent transfusions. People with this subtype need regular monitoring of their iron levels through blood tests and sometimes MRI scans of the liver.
Pregnancy with Hemoglobin H disease requires closer monitoring. If hemoglobin drops below 7 g/dL, regular transfusions every three to four weeks are typically started to keep levels in a safe range for both mother and baby.
Alpha-Thalassemia Major and Survival
For decades, alpha-thalassemia major was considered universally fatal. That has changed. Since the mid-1990s, intrauterine blood transfusions (transfusions delivered to the fetus during pregnancy) have made survival possible. These can begin as early as 18 weeks of gestation and aim to reverse or prevent the dangerous fluid buildup that characterizes the condition.
A registry tracking survivors now includes 90 patients ranging from newborns to adults in their mid-30s. Children who received two or more intrauterine transfusions show better early developmental outcomes than those who received fewer. After birth, these children require lifelong transfusion therapy and management of iron overload, similar to people with severe beta-thalassemia.
Carrier Screening and Family Planning
The American College of Obstetricians and Gynecologists recommends that anyone who is pregnant or considering pregnancy be offered carrier screening for hemoglobin disorders, including alpha-thalassemia. This is especially important if both partners have ancestry from high-prevalence regions, because two carriers of a two-gene deletion could have a child with Hemoglobin H disease or, in certain inheritance patterns common in Southeast Asian populations, alpha-thalassemia major.
If both partners are found to be carriers, prenatal diagnostic tests like chorionic villus sampling (CVS) or amniocentesis can determine whether the fetus is affected. CVS can be performed in the first trimester, giving families more time to understand the diagnosis and plan care. For couples at risk of alpha-thalassemia major, early diagnosis is particularly important because intrauterine transfusions need to begin before hydrops develops for the best outcomes.